Suheung Co., Ltd. (008490.KS)
KRW 12880.0
(-1.68%)
KRW 12880.0
(-1.68%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 6.11 Billion KRW | -81.99% |
| 2022 | 33.98 Billion KRW | -36.7% |
| 2021 | 53.68 Billion KRW | 1.3% |
| 2020 | 52.99 Billion KRW | 67.09% |
| 2019 | 31.71 Billion KRW | 23.25% |
| 2018 | 25.73 Billion KRW | 11.52% |
| 2017 | 23.07 Billion KRW | -15.5% |
| 2016 | 27.3 Billion KRW | 19.55% |
| 2015 | 22.84 Billion KRW | 6.97% |
| 2014 | 21.35 Billion KRW | 74.43% |
| 2013 | 12.24 Billion KRW | 382.39% |
| 2012 | -4.33 Billion KRW | -124.16% |
| 2011 | 17.94 Billion KRW | 38.31% |
| 2010 | 12.97 Billion KRW | 5.12% |
| 2009 | 12.34 Billion KRW | 16.07% |
| 2008 | 10.63 Billion KRW | -7.17% |
| 2007 | 11.45 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.89 Billion KRW | -62.97% |
| 2024 Q1 | 5.11 Billion KRW | 195.68% |
| 2023 Q4 | -5.34 Billion KRW | -4781.34% |
| 2023 FY | 6.11 Billion KRW | -81.99% |
| 2023 Q1 | 6 Billion KRW | 233.86% |
| 2023 Q2 | 5.34 Billion KRW | -10.9% |
| 2023 Q3 | 114.25 Million KRW | -97.86% |
| 2022 Q2 | 9.77 Billion KRW | -27.15% |
| 2022 Q3 | 15.18 Billion KRW | 55.27% |
| 2022 Q4 | -4.48 Billion KRW | -129.54% |
| 2022 Q1 | 13.42 Billion KRW | 52.2% |
| 2022 FY | 33.98 Billion KRW | -36.7% |
| 2021 Q3 | 8.38 Billion KRW | -55.33% |
| 2021 Q4 | 8.81 Billion KRW | 5.16% |
| 2021 FY | 53.68 Billion KRW | 1.3% |
| 2021 Q1 | 17.7 Billion KRW | 86.62% |
| 2021 Q2 | 18.77 Billion KRW | 6.01% |
| 2020 Q1 | 13.39 Billion KRW | 498.86% |
| 2020 FY | 52.99 Billion KRW | 67.09% |
| 2020 Q4 | 9.48 Billion KRW | -22.88% |
| 2020 Q3 | 12.3 Billion KRW | -31.09% |
| 2020 Q2 | 17.85 Billion KRW | 33.33% |
| 2019 FY | 31.71 Billion KRW | 23.25% |
| 2019 Q4 | 2.23 Billion KRW | -73.05% |
| 2019 Q3 | 8.29 Billion KRW | -19.68% |
| 2019 Q1 | 10.85 Billion KRW | 104.88% |
| 2019 Q2 | 10.33 Billion KRW | -4.82% |
| 2018 Q2 | 9.46 Billion KRW | 24.38% |
| 2018 Q3 | 3.35 Billion KRW | -64.56% |
| 2018 Q4 | 5.29 Billion KRW | 57.86% |
| 2018 FY | 25.73 Billion KRW | 11.52% |
| 2018 Q1 | 7.61 Billion KRW | 244.92% |
| 2017 FY | 23.07 Billion KRW | -15.5% |
| 2017 Q4 | 2.2 Billion KRW | -65.36% |
| 2017 Q3 | 6.37 Billion KRW | -28.09% |
| 2017 Q2 | 8.86 Billion KRW | 57.24% |
| 2017 Q1 | 5.63 Billion KRW | -8.86% |
| 2016 FY | 27.3 Billion KRW | 19.55% |
| 2016 Q4 | 6.18 Billion KRW | -5.63% |
| 2016 Q3 | 6.55 Billion KRW | -27.88% |
| 2016 Q2 | 9.08 Billion KRW | 65.62% |
| 2016 Q1 | 5.48 Billion KRW | 1019.17% |
| 2015 Q3 | 6.72 Billion KRW | -24.24% |
| 2015 FY | 22.84 Billion KRW | 6.97% |
| 2015 Q1 | 6.75 Billion KRW | 55.27% |
| 2015 Q2 | 8.87 Billion KRW | 31.46% |
| 2015 Q4 | 490.16 Million KRW | -92.71% |
| 2014 FY | 21.35 Billion KRW | 74.43% |
| 2014 Q4 | 4.34 Billion KRW | -38.5% |
| 2014 Q3 | 7.07 Billion KRW | 43.24% |
| 2014 Q2 | 4.93 Billion KRW | -1.27% |
| 2014 Q1 | 4.99 Billion KRW | 92.16% |
| 2013 Q1 | 3.3 Billion KRW | 121.68% |
| 2013 Q2 | 5.25 Billion KRW | 59.04% |
| 2013 FY | 12.24 Billion KRW | 382.39% |
| 2013 Q4 | 2.6 Billion KRW | 139.07% |
| 2013 Q3 | 1.08 Billion KRW | -79.27% |
| 2012 Q3 | 4.24 Billion KRW | 4.19% |
| 2012 Q2 | 4.07 Billion KRW | 557.81% |
| 2012 Q4 | -15.22 Billion KRW | -458.87% |
| 2012 FY | -4.33 Billion KRW | -124.16% |
| 2012 Q1 | 619.07 Million KRW | 0.0% |
| 2011 Q2 | 4.76 Billion KRW | 25.24% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 17.94 Billion KRW | 38.31% |
| 2011 Q1 | 3.8 Billion KRW | 0.0% |
| 2011 Q3 | 3.83 Billion KRW | -19.61% |
| 2010 Q2 | 6.13 Billion KRW | 445.29% |
| 2010 FY | 12.97 Billion KRW | 5.12% |
| 2010 Q1 | 1.12 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q3 | 3.6 Billion KRW | -41.22% |
| 2009 Q2 | 3.73 Billion KRW | -8.54% |
| 2009 Q1 | 4.08 Billion KRW | 0.0% |
| 2009 FY | 12.34 Billion KRW | 16.07% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 1.79 Billion KRW | -51.99% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 10.63 Billion KRW | -7.17% |
| 2008 Q2 | 2.14 Billion KRW | 24.78% |
| 2008 Q3 | 2.19 Billion KRW | 2.63% |
| 2008 Q1 | 1.71 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 11.45 Billion KRW | 0.0% |
| 2007 Q3 | 6.63 Billion KRW | 222.71% |
| 2007 Q1 | 1.31 Billion KRW | 0.0% |
| 2007 Q2 | 2.05 Billion KRW | 56.03% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 185.215% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 89.448% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 110.269% |
| HANDOK Inc. | -28.79 Billion KRW | 121.249% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 172.716% |
| Yuhan Corporation | 93.5 Billion KRW | 93.456% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 44.983% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 124.662% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 95.815% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -74.406% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 344.143% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 395.058% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 235.236% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 72.6% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 185.215% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 129.221% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -70.767% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 105.174% |
| JW Holdings Corporation | 19.02 Billion KRW | 67.838% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 107.753% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 97.121% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 83.464% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 110.675% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 0.041% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -267.844% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -22.268% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 185.215% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 83.446% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 94.512% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 83.464% |
| Yuhan Corporation | 93.5 Billion KRW | 93.456% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 137.657% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 257.893% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 83.464% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 67.633% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 87.321% |
| CKD Bio Corp. | -24.19 Billion KRW | 125.294% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 74.415% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 77.698% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 79.448% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 110.675% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 86.982% |
| Boryung Corporation | 40.2 Billion KRW | 84.779% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 119.532% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 344.143% |
| JW Lifescience Corporation | 28.14 Billion KRW | 78.257% |